FDA Approves Companion Diagnostic for Immunotherapy Eligible Endometrial Cancer

On April 23, 2021, the U.S. Food and Drug Administration (FDA) approved the Ventana MMR RxDx Panel for patients with advanced or recurrent endometrial cancer. Testing can identify patients eligible for treatment with dostarlimab-gxly, which was also approved by the FDA on April 22, 2021.

Read Roche's announcement.

Posted 4/23/2021